These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 36371985)

  • 1. Epigenomic landscape study reveals molecular subtypes and EBV-associated regulatory epigenome reprogramming in nasopharyngeal carcinoma.
    Ka-Yue Chow L; Lai-Shun Chung D; Tao L; Chan KF; Tung SY; Cheong Ngan RK; Ng WT; Wing-Mui Lee A; Yau CC; Lai-Wan Kwong D; Ho-Fun Lee V; Lam KO; Liu J; Chen H; Dai W; Lung ML
    EBioMedicine; 2022 Dec; 86():104357. PubMed ID: 36371985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancer infestation drives tumorigenic activation of inactive B compartment in Epstein-Barr virus-positive nasopharyngeal carcinoma.
    Mizokami H; Okabe A; Choudhary R; Mima M; Saeda K; Fukuyo M; Rahmutulla B; Seki M; Goh BC; Kondo S; Dochi H; Moriyama-Kita M; Misawa K; Hanazawa T; Tan P; Yoshizaki T; Fullwood MJ; Kaneda A
    EBioMedicine; 2024 Apr; 102():105057. PubMed ID: 38490101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral Microbiota Alteration and Roles in Epstein-Barr Virus Reactivation in Nasopharyngeal Carcinoma.
    Liao Y; Zhang JB; Lu LX; Jia YJ; Zheng MQ; Debelius JW; He YQ; Wang TM; Deng CM; Tong XT; Xue WQ; Cao LJ; Wu ZY; Yang DW; Zheng XH; Li XZ; Wu YX; Feng L; Ye W; Mu J; Jia WH
    Microbiol Spectr; 2023 Feb; 11(1):e0344822. PubMed ID: 36645283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epstein-Barr virus DNA seropositivity links distinct tumoral heterogeneity and immune landscape in nasopharyngeal carcinoma.
    Li W; Lv S; Liu G; Lu N; Jiang Y; Liang H; Xia W; Xiang Y; Xie C; He J
    Front Immunol; 2023; 14():1124066. PubMed ID: 36860875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor molecular landscape of Epstein-Barr virus (EBV) related nasopharyngeal carcinoma in EBV-endemic and non-endemic areas: Implications for improving treatment modalities.
    Lenoci D; Resteghini C; Serafini MS; Pistore F; Canevari S; Ma B; Cavalieri S; Alfieri S; Trama A; Licitra L; De Cecco L
    Transl Res; 2024 Mar; 265():1-16. PubMed ID: 37949350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of genomic alterations in nasopharyngeal carcinoma and nasopharyngeal carcinoma-derived Epstein-Barr virus by whole-genome sequencing.
    Tu C; Zeng Z; Qi P; Li X; Guo C; Xiong F; Xiang B; Zhou M; Liao Q; Yu J; Li Y; Li X; Li G; Xiong W
    Carcinogenesis; 2018 Dec; 39(12):1517-1528. PubMed ID: 30102338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitation of DNA methylation in Epstein-Barr virus-associated nasopharyngeal carcinoma by bisulfite amplicon sequencing.
    Zhao W; Mo Y; Wang S; Midorikawa K; Ma N; Hiraku Y; Oikawa S; Huang G; Zhang Z; Murata M; Takeuchi K
    BMC Cancer; 2017 Jul; 17(1):489. PubMed ID: 28716111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High risk Epstein-Barr virus variants characterized by distinct polymorphisms in the EBER locus are strongly associated with nasopharyngeal carcinoma.
    Hui KF; Chan TF; Yang W; Shen JJ; Lam KP; Kwok H; Sham PC; Tsao SW; Kwong DL; Lung ML; Chiang AKS
    Int J Cancer; 2019 Jun; 144(12):3031-3042. PubMed ID: 30536939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiplex Epstein-Barr virus BALF2 genotyping detects high-risk variants in plasma for population screening of nasopharyngeal carcinoma.
    Miller JA; Sahoo MK; Yamamoto F; Huang C; Wang H; Zehnder JL; Le QT; Pinsky BA
    Mol Cancer; 2022 Jul; 21(1):154. PubMed ID: 35902864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the crosstalk of epigenetic modifications and immune evasion in nasopharyngeal cancer.
    Looi CK; Foong LC; Chung FF; Khoo AS; Loo EM; Leong CO; Mai CW
    Cell Biol Toxicol; 2023 Dec; 39(6):2501-2526. PubMed ID: 37755585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic landscape of Epstein-Barr virus in familial nasopharyngeal carcinoma.
    Zhang WL; Zhang JB; Wang TM; Wu YX; He YQ; Xue WQ; Liao Y; Deng CM; Li DH; Wu ZY; Yang DW; Zheng XH; Li XZ; Zhou T; Zhang PF; Zhang SD; Hu YZ; Jia WH
    J Gen Virol; 2022 Mar; 103(3):. PubMed ID: 35349400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural Variations in BRLF1 Promoter Contribute to the Elevated Reactivation Level of Epstein-Barr Virus in Endemic Areas of Nasopharyngeal Carcinoma.
    Zhang JB; Huang SY; Wang TM; Dong SQ; He YQ; Zheng XH; Li XZ; Wang F; Jianbing M; Jia WH
    EBioMedicine; 2018 Nov; 37():101-109. PubMed ID: 30420297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rare POLN mutations confer risk for familial nasopharyngeal carcinoma through weakened Epstein-Barr virus lytic replication.
    Xiao RW; Wang F; Wang TM; Zhang JB; Wu ZY; Deng CM; Liao Y; Zhou T; Yang DW; Dong SQ; Xue WQ; He YQ; Zheng XH; Li XZ; Zhang PF; Zhang SD; Hu YZ; Liu YY; Xia YF; Gao S; Mu JB; Feng L; Jia WH
    EBioMedicine; 2022 Oct; 84():104267. PubMed ID: 36116213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of methylation status of Epstein-Barr virus DNA C promoter in the diagnosis of nasopharyngeal carcinoma.
    Zheng XH; Wang RZ; Li XZ; Zhou T; Zhang JB; Zhang PF; Lu LX; Jia WH
    Cancer Sci; 2020 Feb; 111(2):592-600. PubMed ID: 31834989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct sequencing and characterization of a clinical isolate of Epstein-Barr virus from nasopharyngeal carcinoma tissue by using next-generation sequencing technology.
    Liu P; Fang X; Feng Z; Guo YM; Peng RJ; Liu T; Huang Z; Feng Y; Sun X; Xiong Z; Guo X; Pang SS; Wang B; Lv X; Feng FT; Li DJ; Chen LZ; Feng QS; Huang WL; Zeng MS; Bei JX; Zhang Y; Zeng YX
    J Virol; 2011 Nov; 85(21):11291-9. PubMed ID: 21880770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment and Characterization of an Epstein-Barr Virus-positive Cell Line from a Non-keratinizing Differentiated Primary Nasopharyngeal Carcinoma.
    Chai AWY; Yee SM; Lee HM; Abdul Aziz N; Yee PS; Marzuki M; Wong KW; Chiang AKS; Chow LK; Dai W; Liu TF; Tan LP; Khoo ASB; Lo KW; Lim PVH; Rajadurai P; Lightfoot H; Barthorpe S; Garnett MJ; Cheong SC
    Cancer Res Commun; 2024 Mar; 4(3):645-659. PubMed ID: 38358347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epstein-Barr viral product-containing exosomes promote fibrosis and nasopharyngeal carcinoma progression through activation of YAP1/FAPα signaling in fibroblasts.
    Lee PJ; Sui YH; Liu TT; Tsang NM; Huang CH; Lin TY; Chang KP; Liu SC
    J Exp Clin Cancer Res; 2022 Aug; 41(1):254. PubMed ID: 35986369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epstein-Barr virus mRNA profiles and viral DNA methylation status in nasopharyngeal brushings from nasopharyngeal carcinoma patients reflect tumor origin.
    Ramayanti O; Juwana H; Verkuijlen SA; Adham M; Pegtel MD; Greijer AE; Middeldorp JM
    Int J Cancer; 2017 Jan; 140(1):149-162. PubMed ID: 27600027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of high-risk EBV strains on nasopharyngeal carcinoma gene expression.
    Lim CY; Ng GWY; Goh CK; Lee MKC; Cheong I; Ooi EE; Liu J; West RB; Loh KS; Tay JK
    Oral Oncol; 2024 Oct; 157():106941. PubMed ID: 39024697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical utility of circulating Epstein-Barr virus DNA analysis for the management of nasopharyngeal carcinoma.
    Fung SY; Lam JW; Chan KC
    Chin Clin Oncol; 2016 Apr; 5(2):18. PubMed ID: 27121878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.